SRC3 expression is downregulated by several natural compounds (e.g., verrucarin A, gambogic acid, thevebioside) (Figure 1b), while SRC3 upregulation has been reported in different malignancies (e.g., breast cancer, ovarian cancer, endometrial cancer, cervical cancer, thyroid cancer, hepatocellular carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, colorectal cancer, bladder cancer, glioma, nasopharyngeal cancer, esophageal squamous cell carcinoma and bone cancer) (Figure 1a) [114]. This evidence concerns the gene NCOA3 and hepatocellular carcinoma.